CHRU de Lille - Hôpital Huriez
- Address
- Rue Michel Polonowski, 59037 Lille, France
Hemic and Lymphatic Diseases
At CHRU de Lille - Hôpital Huriez, clinical research in hematology focuses on serious blood-related disorders, especially Light Chain (AL) Amyloidosis. The trials are designed to assess whether new treatment approaches can improve survival and support better long-term outcomes for patients with advanced disease.
- Evaluating a new therapy alongside standard care for advanced AL amyloidosis
- Studying whether treatment can extend survival in patients with severe blood and plasma cell disease
This area of research reflects a strong focus on improving treatment effectiveness and safety for patients facing a high-risk hematologic disorder.
Digestive System Diseases
The site is also involved in digestive system cancer research, with trials centered on small bowel adenocarcinoma. These studies aim to explore better treatment options for locally advanced or metastatic disease and to understand whether existing chemotherapy strategies can offer improved disease control.
- Testing treatment approaches for small bowel adenocarcinoma
- Assessing how well current therapies help patients remain alive without disease progression
This work highlights a commitment to advancing care in gastrointestinal oncology, with attention to both treatment effectiveness and patient outcomes.
Digestive System and Oral Physiological Phenomena
Research at Hôpital Huriez also touches on broader digestive system physiology, supporting clinical efforts that examine how disease affects normal digestive function and overall patient well-being. In this setting, trials contribute to a better understanding of how treatments may influence symptoms, progression, and quality of life in complex digestive conditions.
- Exploring disease-related changes in digestive function
- Supporting evaluation of treatment impact on patient outcomes in gastrointestinal disease
The research environment brings together oncology and digestive health expertise to support clinical advances for patients in Lille.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHRU de Lille - Hôpital Huriez
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Birtamimab with Standard Care versus Placebo in Mayo Stage IV Light Chain Amyloidosis: A Phase 3 Randomized, Double-Blind Study | Prothena Biosciences Limited | Phase III | Not Recruiting | Oct 2021 | May 2025 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Birtamimab | 1 | Unknown | 2021-10-13 | 2021-10-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.